Research on disease, treatment, and what keeps people well. Coverage runs from lab findings and clinical trials to public health, nutrition, and the health care system.
Aged mice cleared their spent immune cells poorly, and worn-out neutrophils piled up in their organs. Switching off a single macrophage receptor, EP2, restored the clean-up and held back decline across the body, from brain to heart.
Kyushu University researchers were trying to protect HGF, the signal that wakes muscle stem cells, from age-related damage. At double the dose, a small trisulfide compound instead made it grip its receptor twice as tightly as undamaged protein — and nobody yet knows why.
GLP-1 drugs settled the argument that metabolic hormones work. This early-stage candidate, built by AI and delivered as DNA, sketches what round two might look like.
Five-minute folk-song sessions three times daily beat guideline-recommended breathing exercises, with older patients and those with severe symptoms responding best.
A University of Guadalajara team found levodopa-treated mice slipped from near-normal forelimb symmetry to 30.4 per cent by day 30, while mice given levodopa plus freeze-dried bee venom held at 50.9. Separate research on beekeepers, who are stung constantly, found no reduced Parkinson’s risk.
Two predictors that held nationally collapsed under local modeling, while disability tracked breastfeeding in opposite directions in regions only a few hundred miles apart.
In the first adequately powered ARFID trial, family-based treatment moved 98 children from 85.7 to 90.5 per cent of expected body weight while individual therapy left weight flat — but both cut symptoms by the same amount. Every child enrolled was underweight, and 42 per cent of applicants were excluded for not being.
Nearly 20 percent of veterans have used acid, a rate that survives every demographic control, in RAND’s first nationally representative survey — which also finds roughly half don’t know whether disclosing use could cost them their VA benefits.
Rejections rose 67 percent over six years. After a denial, almost half of patients received no drug in the same therapeutic class within 90 days.
A preclinical DNA shot turned mouse muscle into a long-lasting GLP-1 source, outperforming daily semaglutide in early tests.
A NIST study found home gut microbiome tests can give conflicting answers from the same sample. The problem may lie in the tests themselves.
Engineered macrophages struggle to expand and persist as cancer therapies. USC researchers found a way to grow their upstream progenitors on a massive scale by blocking one enzyme. CAR-engineered versions attacked leukemia and solid tumors in mice. A new receptor design even recruited the host’s immune system across mismatch barriers.